KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $35.6 million.

  • Travere Therapeutics' Net Cash Flow rose 87050.48% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 16999.12%. This contributed to the annual value of $1.3 million for FY2024, which is 10049.52% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Net Cash Flow is $35.6 million, which was up 87050.48% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Net Cash Flow ranged from a high of $91.8 million in Q1 2022 and a low of -$147.7 million during Q3 2023
  • Its 5-year average for Net Cash Flow is -$18.7 million, with a median of -$10.9 million in 2024.
  • In the last 5 years, Travere Therapeutics' Net Cash Flow surged by 127514.6% in 2021 and then crashed by 21610.07% in 2022.
  • Travere Therapeutics' Net Cash Flow (Quarter) stood at -$41.6 million in 2021, then tumbled by 169.6% to -$112.2 million in 2022, then rose by 26.8% to -$82.2 million in 2023, then surged by 128.1% to $23.1 million in 2024, then soared by 54.05% to $35.6 million in 2025.
  • Its Net Cash Flow stands at $35.6 million for Q3 2025, versus $11.3 million for Q2 2025 and $2.8 million for Q1 2025.